BridgeBio Pharma (BBIO) FCF Margin (2019 - 2026)
BridgeBio Pharma (BBIO) reported FCF Margin of 101.46% for Q1 2026, up 6937.0% on a YoY basis from 1.44% in Q1 2025, and down 172.02% sequentially from 37.3% in Q4 2025.
BridgeBio Pharma (BBIO) FCF Margin (2019 - 2026) Analysis & Trends
BridgeBio Pharma (BBIO) has 8 years of FCF Margin data on file, last reported at 101.46% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 6937.0% year-over-year to 101.46%; the trailing twelve-month figure through Mar 2026 stood at 76.75% (up 31567.0% YoY), and the FY2025 full-year result was 89.03%, up 14576.0% from the prior year.
- FCF Margin slipped to 101.46% in Q1 2026, from 37.3% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 3474.54% in Q2 2024 to a low of 39042.01% in Q3 2022.
- A 5-year average of 5083.8% and a median of 3320.83% in 2024 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin slumped 3393271 bps in 2022 and surged 3549818 bps in 2023, its largest moves.
- Tracing BBIO's FCF Margin over 5 years: stood at 5240.86% in 2022, then tumbled by 36 bps to 7147.68% in 2023, then soared by 54 bps to 3320.83% in 2024, then jumped by 99 bps to 37.3% in 2025, then sank by 172 bps to 101.46% in 2026.
- Business Quant data shows BBIO's FCF Margin at 101.46% in Q1 2026, 37.3% in Q4 2025, and 90.79% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | BridgeBio Pharma | 16.15 Bn | 15.22 Bn | 184.58 Mn | -101.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -101.46% |
| Dec 31, 2025 | -37.30% |
| Sep 30, 2025 | -90.79% |
| Jun 30, 2025 | -72.97% |
| Mar 31, 2025 | -170.82% |
| Dec 31, 2024 | -3,320.83% |
| Sep 30, 2024 | -6,616.76% |
| Jun 30, 2024 | 3,474.54% |
| Mar 31, 2024 | -104.32% |
| Dec 31, 2023 | -7,147.68% |
| Sep 30, 2023 | -3,543.83% |
| Jun 30, 2023 | -6,933.64% |
| Mar 31, 2023 | -7,904.38% |
| Dec 31, 2022 | -5,240.86% |
| Sep 30, 2022 | -39,042.01% |
| Jun 30, 2022 | -44.70% |
| Mar 31, 2022 | -9,526.86% |
| Dec 31, 2021 | -1,446.92% |
| Sep 30, 2021 | -5,109.30% |
| Jun 30, 2021 | -174.32% |